Efficacy of Ziprasidone Against Hostility in Schizophrenia: Post Hoc Analysis of Randomized, Open-Label Study Data
J Clin Psychiatry 2006;67(4):638-642
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: The objective was to determine
the effects of sequential intramuscular/oral ziprasidone on hostility.
Method: A total of 572 inpatients
diagnosed with DSM-IV schizophrenia or
schizoaffective disorder were the subjects in a randomized,
rater-blinded, 6-week, open-label study comparing
sequential intramuscular and oral ziprasidone with haloperidol. The Brief Psychiatric Rating
Scale (BPRS) was the principal outcome measure. To determine the effect of ziprasidone on
hostility, post hoc analyses of scores on the hostility
item from the BPRS were conducted. Introducing
positive symptoms and akathisia as covariates tested specific antihostility effect. The study
was conducted from October 23, 1998, to August 15, 2000.
Results: Ziprasidone demonstrated
specific antihostility effects over time throughout the 42-day study period and statistically significant superiority to haloperidol on this measure in
the first week of treatment (p = .0149 at first
evaluation [day 1, 2, or 3]; p = .0358 at day 7).
Conclusion: Ziprasidone is an effective
treatment for hostility in patients with
schizophrenia or schizoaffective disorder.